Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   Prednisolone pharmacokinetics in the presence and absence of Ritonavir after oral prednisone administration to healthy volunteers
  2. Penzak, S. R.; Fomnentini, E.; Alfaro, R. M.; Long, M.; Natarajan, V.; Kovacs, J.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, DEC 15; 40(5): 573-580.
  1. 2.   Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
  2. Penzak, S. R.; Shen, J. M.; Alfaro, R. M.; Remaley, A. T.; Natarajan, V.; Falloon, J.
  3. Therapeutic Drug Monitoring. 2004 26(3): 322-330.
  1. 3.   The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix
  2. Li, M.; Phylip, L. H.; Lees, W. E.; Winther, J. R.; Dunn, B. M.; Wlodaawer, A.; Kay, J.; Gustchina, A.
  3. Nature Structural Biology. 2000 7(2): 113-117.
  1. 4.   Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain
  2. Sei, S.; Yang, Q. E.; O'Neill, D.; Yoshimura, K.; Nagashima, K.; Mitsuya, H.
  3. Journal of Virology. 2000 74(10): 4621-4633.
  1. 5.   Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: A lead HIV protease inhibitor
  2. Prasad, J.; Boyer, F. E.; Domagala, J. M.; Ellsworth, E. L.; Gajda, C.; Hamilton, H. W.; Hagen, S. E.; Markoski, L. J.; Steinbaugh, B. A.; Tait, B. D.; Humblet, C.; Lunney, E. A.; Pavlovsky, A.; Rubin, J. R.; Ferguson, D.; Graham, N.; Holler, T.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Urumov, A.; Zeikus, E.; Zeikus, G.; Gracheck, S. J.; Saunders, J. M.
  3. Bioorganic & Medicinal Chemistry. 1999 7(12): 2775-2800.
  1. 6.   Structure-based design of HIV protease inhibitors: pharmacokinetic optimization
  2. Stinson, S. F.; Randad, R. S.; Clanton, D.; House, T.; Lubkowska, L.; Erickson, J. W.
  3. HIV Pathogenesis and Treatment Conference. 1998, 56 (abstract no. 2039).
  1. 7.   Importance of molecular flexibility for the resistance of HIV-1 protease inhibitors
  2. Kato, R.; Yusa, K.; Gulnik, S. V.; Bhat, T.; Hayashi, H.; Mitsuya, H.; Erickson, J. W.
  3. International Conference on AIDS. 1998, 12 67-68.
  1. 8.   Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases
  2. Xie, D.; Gulnik, S.; Collins, L.; Gustchina, E.; Bhat, T. N.; Erickson, J. W.
  3. Advances in Experimental Medicine and Biology. 1998 436: 381-386.
  1. 9.   Application of restriction enzyme analysis to screen drug-resistant mutations in HIV-protease and in proteolytic cleavage sites in the gag region
  2. Vasudevachari, M. B.; Imamichi, T.; Imamichi, H.; Zhang, Y. M.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 176 (abstract no. 606).
  1. 10.   Emergence of drug resistant HIV variants with mutations in the protease gene and gag cleavage sites during indinavir therapy
  2. Zhang, Y. M.; Imamichi, H.; Falloon, J.; Lane, H. C.; Vasudevachari, M. B.; Imamichi, T.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 175 (abstract no. 602).
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel